Trump Sets 200% Tariff on Generic Drugs by 2029, Offering Two-Year Reshoring Window
The US will keep generic medicine imports duty-free until August 2028, then impose 100% tariffs for a year and 200% thereafter, a move aimed at forcing pharmaceutical production back to America.
President Donald Trump announced on 21 July that generic medicines imported into the United States will remain tariff-free for two years from 1 August 2026, after which duties will rise to 100 per cent for one year and then to 200 per cent. The phased timeline, posted on Truth Social, marks the first time generic drugs have been explicitly targeted in the administration’s trade-policy arsenal, having been excluded from the 100 per cent tariffs imposed on branded pharmaceuticals in April. The immediate effect is to grant a transition period while signalling that the cost of relying on foreign production will become prohibitive.
The mechanism is designed as a penalty for companies that do not build manufacturing plants and equipment in the United States within the stated timeframe. Trump said the policy aims to “reshore” generic pharmaceutical production and protect American patients, while leaving unchanged the existing tariff regime for patented and innovative drugs—under which major firms such as Pfizer, AstraZeneca and Novo Nordisk have already struck pricing and investment deals to secure exemptions. The legal basis was not specified, though earlier pharmaceutical tariffs were enacted under Section 232 national-security authority, which was not affected by the Supreme Court ruling that struck down the administration’s blanket global tariffs.
Viewed from New Delhi, the announcement carries significant weight. India supplies an estimated 40–50 per cent of generic prescriptions dispensed in the US, with exports worth $9.7 billion in 2025, or 38 per cent of its total pharmaceutical exports. Indian-made generics saved the American healthcare system $219 billion in 2022 alone, according to industry data. Analysts in Mumbai caution that the two-year window is shorter than the typical three years needed to build a new manufacturing plant, raising the prospect that some Indian firms may reduce their US exposure rather than absorb the tariffs. China, the dominant producer of active pharmaceutical ingredients, also faces disruption, though the policy directly targets finished-dose generics. In Washington, the generic-industry trade group said it was seeking details, while economists warn that domestic production is unlikely to match the cost efficiency of current supply chains, potentially pushing up medicine prices for American consumers.
The generic-drug tariff is part of a broader trade offensive. In recent days, the US has announced a 50 per cent surtax on certain Canadian goods and 25 per cent duties on Brazilian imports, and the US Trade Representative has signalled that new tariffs on around 60 countries over forced-labour concerns could be unveiled shortly. The temporary 10 per cent global tariff is due to expire this week. The next concrete milestone for the pharmaceutical sector is 1 August 2026, when the two-year duty-free period formally begins, followed by the first tariff increase on 1 August 2028.
| Indian & South Asian press | −0.60 | critical |
|---|---|---|
| Latin American press | 0.00 | neutral |
| Continental European press | −0.30 | critical |
| Southeast Asian press | 0.00 | neutral |
India suffers a heavy blow: Trump's decision penalizes Indian generic manufacturers, who now must prepare for unsustainable tariffs.
By emphasizing the phased nature and the eventual high cost, the Indian narrative creates a sense of urgency and victimization, presenting the policy as a targeted attack on Indian industry.
The United States imposes tariffs on generic drugs to boost domestic production, without mentioning effects on Latin America.
By adopting a purely descriptive tone and focusing on the timeline, Latin American media normalize the decision as an ordinary trade policy measure, avoiding any judgment or alarm.
Omits any discussion of potential impact on Latin American generic drug producers, such as Mexico or Brazil, which could be affected by the tariffs.
Europe is warned: Trump uses tariffs as leverage to force pharmaceutical companies to move production to the United States.
By using language of threat and warning, European media turn the announcement into an ultimatum, emphasizing the stakes for European industry and the coercive nature of the policy.
Omits the perspective of developing countries like India, which heavily depend on generic exports and are most affected.
The United States announces progressive tariffs on generics, but the Southeast Asian region is not directly affected.
By maintaining a detached tone and emphasizing the lack of direct impact, Southeast Asian media minimize the policy's relevance to their region, presenting it as a US domestic affair.
Omits the possibility of disruptions in global supply chains, an aspect highlighted by European media.
Broaden your view
Zelensky Sacks Army Chief Syrskyi After Protests, Names Drapatyi Successor
9 languages · 41 outlets
From TechnologyOpenAI Models Breach Sandbox, Autonomously Hack Hugging Face During Test
8 languages · 16 outlets
From Science & HealthLegume-Rich Diets Linked to 30% Lower Hypertension Risk, Global Review Finds
7 languages · 9 outlets